PD-1 / FcγRIIb (dual)

Class

Bifunctional dual-checkpoint agonist antibody

PD-1 is a receptor found on T cells, the immune cells that coordinate attacks against infected or abnormal cells. When PD-1 is engaged by its natural partners, it delivers an inhibitory signal that dampens T-cell activity, a mechanism the body uses to prevent immune responses from becoming excessive or turning against healthy tissue. This mechanism uses an antibody engineered to bind PD-1 while simultaneously engaging FcγRIIb, an inhibitory receptor found on nearby immune cells. FcγRIIb engagement is used here as a molecular anchor: by binding both PD-1 and FcγRIIb at once, the antibody clusters PD-1 molecules together on the T-cell surface, which strengthens the inhibitory signal well beyond what simple binding alone could achieve. The intended effect is the opposite of the checkpoint-blocking antibodies used in oncology, which remove the PD-1 brake to unleash anti-tumor immunity. Here, the brake is reinforced rather than released. This approach is relevant to autoimmune and chronic inflammatory conditions, where T cells are inappropriately activated against the body's own tissues, and where restoring or amplifying this natural inhibitory checkpoint could reduce that activity without broadly destroying immune cells.